HomeAI · summaries
Storia in 2 fonti
‘Dozens’ of treatments for chronic itch under investigation
CLEVELAND — After more than a decade with no new medications for chronic spontaneous urticaria, clinicians are beginning to see rapid progress, according to a speaker at the Medical Dermatology Therapy Update IV. FDA approvals of the biologic dupilumab (Dupixent, Sanofi and Regeneron) and twice-daily oral therapy remibrutinib (Rhapsido, Novartis) for chronic spontaneous urticaria in 2025
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
‘Dozens’ of treatments for chronic itch under investigation
CLEVELAND — After more than a decade with no new medications for chronic spontaneous urticaria, clinicians are beginning to see rapid progress, according to a speaker at the…
- ·
medpagetoday.com
Chronic Spontaneous Urticaria Is More Than IgE: New Pathways Drive Targeted Care
Emerging data are reshaping how clinicians match patients to therapy